Leerink Partners analyst Geoff Porges maintained a Hold rating on Radius Health (NASDAQ:RDUS) on Tuesday, setting a price target of $26, which is approximately 22.82% above the present share price of $21.17.
Porges expects Radius Health to post earnings per share (EPS) of -$0.35 for the fourth quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Hold rating of shares in Radius Health, with an average price target of $24.33.
The analysts price targets range from a high of $33 to a low of $18.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $51.8 million and a net profit of -$11.89 million. The company's market cap is $1 billion.
According to TipRanks.com, Leerink Partners analyst Geoff Porges is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 1.9% and a 45.95% success rate.
Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.